TY - JOUR
T1 - Edoxaban versus warfarin in patients with atrial fibrillation
AU - ENGAGE AF-TIMI 48 Investigators
AU - Giugliano, Robert P.
AU - Ruff, Christian T.
AU - Braunwald, Eugene
AU - Murphy, Sabina A.
AU - Wiviott, Stephen D.
AU - Halperin, Jonathan L.
AU - Waldo, Albert L.
AU - Ezekowitz, Michael D.
AU - Weitz, Jeffrey I.
AU - Špinar, Jindřich
AU - Ruzyllo, Witold
AU - Ruda, Mikhail
AU - Koretsune, Yukihiro
AU - Betcher, Joshua
AU - Shi, Minggao
AU - Grip, Laura T.
AU - Patel, Shirali P.
AU - Patel, Indravadan
AU - Hanyok, James J.
AU - Mercuri, Michele
AU - Antman, Elliott M.
AU - Peruzzotti-Jametti, Luca
AU - Malynovsky, Yaroslav
AU - Morin, S. E.
AU - Hoffman, E. B.
AU - Deenadayalu, N.
AU - Lanz, H.
AU - Curt, V.
AU - Duggal, A.
AU - Davé, J.
AU - Morgan, D.
AU - Choi, Y.
AU - Shi, M.
AU - Jin, J.
AU - Xie, J.
AU - Crerand, W.
AU - Kappelhof, J.
AU - Maxwell, W.
AU - Skinner, M.
AU - Selicato, G.
AU - Otto, C.
AU - Reissner, C.
AU - Smith, K.
AU - Ostroske, J.
AU - Ron, A.
AU - Connolly, S.
AU - Camm, J.
AU - Ito, T.
AU - Ozaki, Y.
AU - Watanabe, E.
PY - 2013
Y1 - 2013
N2 - BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)
AB - BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)
UR - http://www.scopus.com/inward/record.url?scp=84888362796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888362796&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1310907
DO - 10.1056/NEJMoa1310907
M3 - Article
C2 - 24251359
AN - SCOPUS:84888362796
SN - 0028-4793
VL - 369
SP - 2093
EP - 2104
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 22
ER -